Thalidomide in toxic epidermal necrolysis

被引：19

作者：

Klausner, JD ^{[1
]}

Kaplan, G

Haslett, PAJ

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94103 USA

[2] Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA

来源：

LANCET | 1999年 / 353卷 / 9149期

关键词：

D O I：

10.1016/S0140-6736(05)74905-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：324 / 324

页数：1

共 5 条

[1]

Chao N J, 1996, Biol Blood Marrow Transplant, V2, P86

[2] The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus [J].

Haslett, P ;

Hempstead, M ;

Seidman, C ;

Diakun, J ;

Vasquez, D ;

Freedman, VH ;

Kaplan, G .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (12) :1047-1054

[3] Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].

Haslett, PAJ ;

Corral, LG ;

Albert, M ;

Kaplan, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892

[4] Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use [J].

Klausner, JD ;

Freedman, VH ;

Kaplan, G .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 81 (03) :219-223

[5] Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis [J].

Wolkenstein, P ;

Latarjet, J ;

Roujeau, JC ;

Duguet, C ;

Boudeau, S ;

Vaillant, L ;

Maignan, M ;

Schuhmacher, MH ;

Milpied, B ;

Pilorget, A ;

Bocquet, H ;

Brun-Buisson, C ;

Revuz, J .

LANCET, 1998, 352 (9140) :1586-1589

← 1 →